Neuroendocrine tumors of the lung

Current Opinion in Oncology

Volumn 20, Issue 2, 2008, Pages 148-154

  García Yuste, Mariano ^a   Matilla, José M ^a   González Aragoneses, Federico ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Large cell neuroendocrine carcinoma; Neuroendocrine lung carcinoma; Occult neuroendocrine differentiation

Indexed keywords

CISPLATIN; ETOPOSIDE; INTERFERON; OCTREOTIDE; PASIREOTIDE; PLATINUM DERIVATIVE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHADENECTOMY; META ANALYSIS; MORBIDITY; NEUROENDOCRINE TUMOR; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW;

CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS;

EID: 39849102972     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f35ed3     Document Type: Review

References (50)

1. García-Yuste M, Matilla JM, Alvarez Gago T, et al., the Spanish Multicenter Study of Neuroendocrine Tumors of the Lung (EMETNE-SEPAR). Prognostic factors in neuroendocrine lung tumors: A Spanish Multicenter Study. Ann Thorac Surg 2000; 70:258-263.
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-1717.
3. García-Yuste M, Molins L, Matilla JM, et al. Trends of prognostic factors in neuroendocrine lung tumors [in Spanish]. Arch Bronconeumol 2007; 43:549-556. Histological type and lymph node involvement show the greatest influence on survival.
4. García-Yuste M, Matilla JM, Cueto A, et al., the Spanish Multicentric Study of Neuroendocrine Tumours of the Lung for the Spanish Society of Pneumonology and Thoracic Surgery (EMETNESEPAR). Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multicentric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007; 31:192-197. Systematic mediastinal lymphadenectomy should always be performed.
5. Travis WD, Sobin LH. Histologic typing of lung and pleural tumours; international histologic classification of tumours. (No. 1). New York, NY: Springer-Verlag; 1999.
6. Thomas CH F, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids. Outcome in patients presenting with regional lymph node involvement. Chest 2001; 119:1143-1150.
7. Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: Nodal status and long-term survival after resection. Ann Thorac Surg 2004; 77:1781-1785.
8. Dodoli CH, Barlesi F, Chetaille B, et al. Large cell neuroendocrine carcinoma of the lung: An aggressive disease potentially treatable with surgery. Ann Thorac Surg 2004; 77:1168-1172.
9. Mezzetti M, Raveglia F, Panigalli T, et al. Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification. Ann Thorac Surg 2003; 76:1838-1842.
10. Filosso PL, Rena O, Donati G, et al. Bronchial carcinoid tumors: Surgical management and long-term outcome. J ThoracCardiovasc Surg 2002; 123:303-309.
11. Inoue M, Miyoshi S, Yasumitsu T, et al., the Thoracic Surgery Study Group of Osaka. Surgical results for small cell lung cancer based on the new TNM staging system. Ann Thorac Surg 2000; 70:1615-1619.
12. Zacharias J, Nicholson AG, Ladas GP, Goldstraw P. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: Prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg 2003; 75:348-352.
13. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma. A structural, immunohistochemical and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15:529-553.
14. Paci M, Cavazza A, Annessi V, et al. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 2004; 77:1163-1167.
15. Mazières J, Daste GH, Molinier L, et al. Large cell neuroendocrine carcinoma of the lung: pathological study and clinical outcome of 18 resected cases. Lung Cancer 2002; 37:287-292.
16. Fernandez FG, Battafarano RJ. Large-cell neuroendocrine carcinoma of the lung. Cancer Control 2006; 13:270-275. Efforts to identify effective adjuvant therapies are needed to improve treatment outcomes with this aggressive type of lung cancer.
17. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002; 124:285-292.
18. Iyoda A, Hiroshima K, Toyozaki T, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001; 91:1992-2000.
19. Dresler CM, Ritter JH, Patterson GA, et al. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 1997; 63:180-185.
20. Battafarano RJ, Fernandez FG, Ritter J, et al. Large cell neuroendocrine carcinoma: an aggressive form of nonsmall cell lung cancer. J Thorac Cardiovasc Surg 2005; 130:166-172.
21. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006; 24:70-76. Future studies should clarify the histology-specific sensitivity to treatment, especially with regard to chemoradiotherapy.
22. Hage R, Seldenrijk K, de Bruin P, et al. Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg 2003; 23:457-460.
23. Iyoda A, Hiroshima K, Moriya Y, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg 2006; 2:1802-1807. Adjuvant chemotherapy consisting of cisplatin and VP-16 after surgery appears promising for the improvement of the prognosis for patients with completely resected LCNEC.
24. Brambilla E. Large cell carcinoma. Pathology and genetics. In: Travis W, Brambilla E, Müller-Hermelink, Harris CG, editors. Tumours of the lung. Lyon: IARC Press; 2004. pp. 45-50.
25. Graziano SL, Tarum AH, Newman NB, et al. The prognostic significance of neuroendocrine markers of carcinoembryonic antigen on patients with resected stage I and II nonsmall cell cancer. Cancer Res 1994; 54:2908-2913.
26. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation and clinical behavior in nonsmall cell lung cancer: the LCSG experience. Chest 1994; 106:367S-371S.
27. Howe MC, Chapman A, Kerr K, et al. Neuroendocrine differentiation in nonsmall cell lung cancer and its relation to prognosis and therapy. Histopathology 2005; 46:195-201.
28. Carnaghi C, Rimassa L, Garassino I, Santoro A. Clinical significance of neuroendocrine phenotype in nonsmall-cell lung cancer. Ann Oncol 2001; 12:S119-S123.
29. Schleusener JT, Tazelaar HD, Jung S, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy treated nonsmall cell carcinoma. Cancer 1996; 77:1284-1291.
30. Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognosis factor in nonsmall cell lung cancer. Lung Cancer 1993; 10:209-219.
31. Sundaresan V, Reeve JG, Stenning S, et al. Neuroendocrine differentiation and clinical behaviour in nonsmall cell lung tumours. Br J Cancer 1991; 64:333-338.
32. Poola I, Graziano SL. Expression of NSE, Chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines. J Exp Clin Cancer Res 1998; 17:165-173.
33. Lyda MH, Weiss LM. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 2000; 31:980-987.
34. Hiroshima K, Iyoda A, Shibuya K, et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg 2002; 73:1732-1735.
35. Linnoila RI, Mulshine JL, Steinberg SM, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol 1988; 90:641-652.
36. Graziano SL, Mazid R, Newman N, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with nonsmall-cell lung cancer. J Clin Oncol 1989; 7:1398-1406.
37. Gonzalez-Aragoneses F, Moreno-Mata N, Cebollero-Presmanes M, et al. Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. Cancer 2007; 110:1776-1781. Stage I of squamous carcinoma and adenocarcinoma of the lung with synaptophysin+ has a poor prognosis, with a higher frequency of recurrence and lower survival rates.
38. Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer 2003; 97:2487-2497.
39. Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation: an entity of no clinical or prognostic significance. Am J Surg Pathol 2007; 31:26-32. Neuroendocrine differentiation has no clinical or prognostic significance when a wider subset of histological variants is analyzed.
40. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36:228-247.
41. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24:389-427.
42. Ono K, Suzuki T, Miki Y, et al. Somatostatin receptor subtypes in human nonfunctioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res 2007; 27:2231-2239. SOM230 significantly reduced cell proliferation while the conventional analog SMS201-995 did not.
43. Oddstig J, Bernhardt P, Nilsson O, et al. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer invitro. Nucl Med Biol 2006; 33:841-846. The uptake of 177Lu-DOTA-Tyr3- octreotate increased in SCLC cells after exposure to irradiation, probably due to upregulation of sstr expression.
44. Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004; 44:213-220.
45. Iyoda A, Hiroshima K, Moriya Y, et al. Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary nonsmall cell carcinoma. J Thorac Cardiovasc Surg 2006; 132:312-315.
46. Veronesi G, Morandi U, Alloisio M, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 2006; 53:111-115.
47. Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol 2007; 25:4137-4145.
48. Schild SE, Bonner JA, Hillman S, et al. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and ectoposide in limited stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol 2007; 25:3124-3129. Prophylactic cranial irradiation improves survival among those with a complete remission to primary therapy.
49. Samson DJ, Seidenfeld J, Simon GR, et al., American College of Chest Physicians. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl):314S-323S.
50. Simon GR, Turrisi A, American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl):324S-339S.